European Commission Approves CASGEVY™ for Sickle Cell Disease and Beta Thalassemia
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) has announced that the European Commission has granted conditional marketing authorization to CASGEVY™ (exagamglogene autotemcel [exa-cel]), a CRISPR/Cas9 gene-edited therapy. CASGEVY is now approved for…
FDA Grants Priority Review to Bristol Myers Squibb’s Augtyro™ (repotrectinib) Application for Treating Patients with NTRK-Positive Advanced Solid Tumors
Bristol Myers Squibb has disclosed that the U.S. Food and Drug Administration (FDA) has accepted the supplemental New Drug Application (sNDA) for Augtyro™ (repotrectinib) to treat adult and pediatric patients…
AbbVie Completes Acquisition of Immunogen
Today marks the completion of AbbVie’s acquisition of ImmunoGen (NASDAQ: IMGN), solidifying ImmunoGen’s integration into AbbVie’s portfolio. Robert A. Michael, AbbVie’s president and chief operating officer, expressed enthusiasm about the…
Lupin Launches Bromfenac Ophthalmic Solution, 0.075% in the United States
Lupin Limited, a prominent global pharmaceutical company, has unveiled the launch of Bromfenac Ophthalmic Solution, 0.075%, following its approval by the United States Food and Drug Administration (U.S. FDA). This…
Give yourself credit for what you can achieve
The significance of maintaining health and well-being cannot be overstated, especially for individuals living with epilepsy, where the impacts of poor physical health, mental well-being, and overall quality of life…
CRISPR Therapeutics Unveils $280 Million Direct Offering
CRISPR Therapeutics (Nasdaq: CRSP), a leading biopharmaceutical company dedicated to pioneering transformative gene-based therapies for serious illnesses, has announced a strategic move in securing approximately $280 million through a registered…
European Commission Approves CASGEVY™ for SCD and TDT Treatment
CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company dedicated to pioneering gene-based treatments for severe illnesses, disclosed today that the European Commission has granted conditional marketing authorization for CASGEVY™ (exagamglogene autotemcel…
New Findings from Phase 3 Trials of Bimekizumab in Moderate to Severe Hidradenitis Suppurativa to be Revealed at EHSF 2024
Results from the latest analyses of bimekizumab phase 3 trials in patients with moderate to severe hidradenitis suppurativa (HS) will be presented at the 13th Conference of the European Hidradenitis…
Baxter Releases Financial Results for Q4 and FY 2023
Today, Baxter, a prominent player in the global medtech arena, disclosed its financial outcomes for the fourth quarter and the entirety of 2023, concluding on December 31st. Additionally, the company…
Novartis Secures Approval for Expanded Paediatric Chronic Heart Failure Indication for Entrust® Tablet, an Angiotensin Receptor Neprilysin Inhibitor (ARNI)
Otsuka Pharmaceutical Co., Ltd. (Otsuka) announces that Novartis Pharma K.K. (Novartis Pharma) has received approval for an expanded treatment indication of pediatric chronic heart failure for Entresto® Tablets, an angiotensin…
Revamped Bon Curry NEO Line: Otsuka Foods Introduces Five Enhanced Products for a Flavorful Relaunch, Arriving in Stores on March 4, 2024
Today’s announcement unveils Otsuka Foods’ plans to introduce five revamped Bon Curry NEO products, each boasting a richer flavor profile, all under the renowned Bon Curry brand. Set for release…
Otsuka and Jolly Good Initiate Distribution of FACEDUO Content to Aid Families Supporting Individuals with Severe Social Withdrawal
Otsuka Pharmaceutical Co., Ltd. (Otsuka) and Jolly Good Inc. (Jolly Good) have commenced the delivery of innovative content aimed at supporting families of individuals in Japan grappling with severe social…